Section 1: Company Fundamentals

1.1 Company Overview and Performance summary

Company Overview:

Bristol-Myers Squibb Company (NYSE: BMY) is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics.

This US Inflation Report covers the Company Overview & Price performance, Summary table, Key positives & negatives, Key metrics, Company details, technical guidance & Stock recommendation, and Price chart.

Price Performance:

• BMY's share price has corrected by 8.18% in the past three months. Similarly, in the long term, the stock has corrected by 12.78% over the past year.
• The stock is currently trading near to the lower end of its 52-week range of USD 44 and 52-week low price of USD 59.45, with the expectations of an upside movement from the current support levels.
• The price is currently below its short-term (50-day) SMA and long-term (200-day) SMA, with the current RSI of around 39.29.

1.2 Summary Table

1.3 The Key Positives & Negatives

1.4 Key Metrics
Bristol Myers Squibb (BMY) has effectively managed its expenditures, maintaining revenue stability even in periods of rising global inflation. This strategic approach has resulted in superior net margins compared to its industry peers. Additionally, BMY has made notable progress in enhancing its Return on Equity (ROE) over the past year. This prudent financial management demonstrates BMY's resilience in navigating economic challenges, safeguarding profitability, and ensuring a favorable position within the competitive landscape. By optimizing spending and fortifying revenue streams, the company has not only sustained its financial health but has also elevated its profitability metrics, exemplified by its improved ROE. This signifies BMY's commitment to delivering value to shareholders while weathering economic uncertainties.

Section 2: Bristol-Myers Squibb Company (“Buy” at the closing market price of USD 59.97, as of September 07, 2023)

2.1 Company Details

2.2 Technical Guidance and Stock Recommendation  

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is September 07, 2023. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: The report publishing date is as per the Pacific Time Zone.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

 Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

 Stop-loss: It is a level to protect against further losses in case of unfavorable movement in the stock prices.